|
Patients should benefit from greater access under new patent package proposals |
Medicines for Europe |
28 Apr 2023 |
Health & Consumers |
|
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies |
Medicines for Europe |
17 Nov 2022 |
Health & Consumers |
|
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition |
Medicines for Europe |
27 Oct 2022 |
Health & Consumers |
|
Protecting health: Active generic and biosimilar policies central to EU pharmaceutical strategy |
Medicines for Europe |
03 Mar 2020 |
Health & Consumers |
|
Reaction to EU Pharmaceutical legislation: Timely and equitable access for patients and security of supply essential for reform |
Medicines for Europe |
27 Apr 2023 |
Health & Consumers |
|
Ready to drive access to medicines |
Medicines for Europe |
24 Jul 2019 |
Health & Consumers |
|
Regulatory reforms critical to improve patient access to medicines |
Medicines for Europe |
24 Jan 2022 |
Health & Consumers |
|
Report identifies 9 key ingredients to improve access to medicines in the hospital setting |
Medicines for Europe |
08 Oct 2019 |
Health & Consumers |
|
Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come |
Medicines for Europe |
18 Jan 2018 |
Health & Consumers, InfoSociety |
|
Repurposing: a golden opportunity for patient centric health investment in Europe |
Medicines for Europe |
06 Apr 2022 |
Health & Consumers |
|
Risk that European Council will “neuter” SPC manufacturing waiver and give foreign (non-EU) manufacturers strong advantage over EU-based manufacturers |
Medicines for Europe |
12 Oct 2018 |
Health & Consumers |
|
Smart Pharmacovigilance Essential for Patient Safety |
Medicines for Europe |
29 Jan 2020 |
Health & Consumers |
|
Smart policies will encourage more critical medicines manufacturing in Europe |
Medicines for Europe |
26 Feb 2021 |
Health & Consumers |
|
Smart reform of EU pharma and IP legislation key to boosting access to essential medicines |
Medicines for Europe |
30 Jun 2022 |
Health & Consumers |
|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
04 Feb 2021 |
Health & Consumers |
|
SPC manufacturing waiver cannot be derailed by foreign vested interests |
Medicines for Europe |
07 Feb 2019 |
Health & Consumers |
|
SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform |
Medicines for Europe |
18 Sep 2018 |
Health & Consumers |
|
SPC manufacturing waiver, Competition policy, Brexit, pharma incentives European Patent Office take centre stage at 14th Legal Affairs Conference |
Medicines for Europe |
25 Apr 2018 |
Health & Consumers |
|
Stronger mandate for European Medicines Agency should prioritise patient access to medicines |
Medicines for Europe |
24 Jan 2022 |
Health & Consumers |
|
Supply chain commitment to tackling problem of medicine shortages |
Medicines for Europe |
02 Mar 2018 |
Health & Consumers |
|
The EU must stop the offshoring of essential medicines manufacturing investments: ambitious, open and coherent policies must support competitive, robust and sustainable production of APIs and medicines |
Medicines for Europe |
23 Nov 2021 |
Global Europe |
|
The European Commission needs to prioritise equitable access to biosimilar medicines in Europe |
Medicines for Europe |
25 Jan 2022 |
Health & Consumers |
|
The European Medicines Verification System (EMVS) celebrates 1 year of successful operation across Europe |
Medicines for Europe |
07 Feb 2020 |
Health & Consumers, InfoSociety |
|
The off-patent medicines industry is a vital part of the solution for healthcare resilience |
Medicines for Europe |
30 Jun 2022 |
Health & Consumers |
|
Time to modernise the eu pharmaceutical regulatory framework to deliver on access |
Medicines for Europe |
30 Jan 2020 |
Health & Consumers, InfoSociety |
|
US interference unacceptable in EU legislative proposal for an SPC manufacturing waiver |
Medicines for Europe |
22 Oct 2018 |
Health & Consumers |
|
Value added medicines: Continuous innovation crucial to improve healthcare across Europe |
Medicines for Europe |
21 Nov 2018 |
Health & Consumers |
|
Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation |
Medicines for Europe |
05 Sep 2017 |
Health & Consumers |
|
Vigilance saves lives! More focus needed on sustainability and patient engagement |
Medicines for Europe |
24 Jan 2018 |
Health & Consumers |
|
Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks |
Medicines for Europe |
19 Jan 2021 |
Health & Consumers |
